Table.1.
Characteristics of the studies in meta-analysis for the diagnosis of PJI applying Calprotectin
| Study | Year | Country | Study design | Gender (M/F) | Mean age* | BMI* | Detection method | Cutoff values | Gold standard |
|---|---|---|---|---|---|---|---|---|---|
| Dariusz Grzelecki et al | 2021 | Poland | P | 25/60 | 68.3 / 65.5 | 29.3/ 29.9 | Immunoturbidimetric Calprotectin Immunoassay (GCal, Gentian, Moss, Norway) | 1.5 mg/L | ICM (2018) |
| Jared Warren et al | 2021 | USA | P | 57/66 | 65.4 / 66.9 | 32.0/ 34.2 | Lyfstone Calprotectin Point of Care Test Kit (Lyfstone) | 50 mg/L | MSIS (2013) |
| Alexander J Trotter et al | 2020 | TUK | R | 37/32 | NA | NA | The Lyfstone calprotectin test (Lyfstone AS, Tromsø, Norway) | 14 mg/L | ICM (2018) |
| Marjan Wouthuyzen-Bakker et al | 2017 | Netherlan-ds | P | 25/36 | 60/65 | NA | The Rapid Calprotectin High Range Quantum Blue Assay (BÜHLMANN laboratories AG) | 50 mg/L | MSIS (2011) |
| Marjan Wouthuyzen-Bakker et al | 2018 | Netherlan-ds | P | NA | NA | NA | The Rapid Calprotectin High Range Quantum Blue Assay (BÜHLMANN laboratories AG) | 50 mg/L | MSIS (2011) |
| Paolo Salari et al | 2019 | Italy | P | 36/40 | NA | NA | Calprest NG (Eurospital, Trieste, Italy) | 50 mg/L | ICM (2018) |
| Zeyu Zhang et al | 2019 | China | P | 20/43 | NA | NA | ELISA (Hycult Biotech, Uden, the Netherlands) | 173 ug/ml | MSIS (2013) |
*The values were given as the number with Non-PJI / PJI, P prospective study, R retrospective study, NA not applicable